U.S. Luxury Stock News

NasdaqGS:UDMY
NasdaqGS:UDMYConsumer Services

Does Udemy’s AI Microlearning Push In Korea With LG CNS Transform The Bull Case For UDMY?

Earlier this month, Udemy announced a new AI-powered microlearning experience and a partnership with LG CNS that brings its AI learning platform to more than 500 Korean enterprises via LG CNS’s AX Platform. Together, these moves highlight how Udemy is using AI to reshape course delivery while tapping Korea’s innovation-focused corporate sector to deepen its enterprise footprint across Asia-Pacific. We’ll now look at how Udemy’s AI-driven microlearning rollout, especially its LG CNS...
NYSE:KW
NYSE:KWReal Estate

The Bull Case For Kennedy-Wilson Holdings (KW) Could Change Following Harborside 8 Financing Role - Learn Why

Earlier in 2025, JLL’s Capital Markets group arranged US$306 million in senior non-recourse construction financing and US$78 million in preferred equity for the 678-unit Harborside 8 luxury waterfront multifamily project in Jersey City, with Kennedy-Wilson providing the floating-rate senior loan. This financing deepens Kennedy-Wilson’s partnership with the development team and underscores its focus on large-scale, higher-end rental housing projects in growth corridors. We’ll now examine how...
NasdaqGM:MRUS
NasdaqGM:MRUSBiotechs

Merus (MRUS): Reassessing Valuation After a 120% Year-to-Date Rally and Strong Multi-Year Returns

Merus (MRUS) has quietly turned into one of the stronger biotech performers this year, with the stock up more than 120% year to date as investors reprice its antibody pipeline potential. See our latest analysis for Merus. That kind of rerating has not come out of nowhere, with Merus enjoying a powerful 90 day share price return of 42.16% and a standout three year total shareholder return of 597.77%. This suggests momentum is still firmly building around its pipeline story. If Merus has caught...
OTCPK:IRBT.Q
OTCPK:IRBT.QConsumer Durables

iRobot (IRBT): Valuation Check After Chapter 11 Filing and Nasdaq Delisting Decision

iRobot (IRBT) just hit two major turning points at once: a voluntary Chapter 11 filing and a Nasdaq delisting notice, effectively signaling the endgame for its public equity story. See our latest analysis for iRobot. Those Chapter 11 and delisting headlines basically crystallise what the share price had been hinting at for a while. A 1 year total shareholder return of around minus 91 percent and multi year losses show that momentum has not just faded; it has largely evaporated, as equity...
NasdaqGM:RILY
NasdaqGM:RILYCapital Markets

B. Riley Financial (RILY) Q2 Profit From Discontinued Ops Tests Long-Running Bearish Narrative

B. Riley Financial (RILY) has swung back to positive quarterly earnings in Q2 2025, posting revenue of about $199 million and EPS of roughly $2.23, even as trailing 12 month figures still reflect sizable losses. The company has seen revenue move from about $38 million in Q2 2024 to nearly $199 million in Q2 2025, while quarterly EPS has shifted from roughly negative $14.86 to positive $2.23. This sets up a sharp contrast between the latest quarter and its loss making recent history and puts...
NYSE:YEXT
NYSE:YEXTSoftware

Yext (YEXT): Assessing Valuation After a Steady 30% Year-to-Date Share Price Climb

Yext (YEXT) has quietly outperformed many software peers this year, and that kind of steady climb usually means investors see something durable in the story, not just a passing sentiment shift. See our latest analysis for Yext. At a share price of $8.51, Yext’s steady year to date share price return of just over 30 percent and 1 year total shareholder return above 31 percent suggest momentum is still building as investors reassess its growth and profitability profile. If Yext’s climb has you...
NasdaqCM:SNDL
NasdaqCM:SNDLPharmaceuticals

Why SNDL (SNDL) Is Up 12.3% After Renewing Buybacks Amid US Cannabis Rescheduling Hopes

Recently, SNDL Inc. renewed its share repurchase program of up to C$100 million and saw sentiment strengthen after reports that the Trump administration may push to reclassify marijuana to Schedule III in the US, a move that could ease tax and financing constraints across the cannabis industry. Although SNDL remains primarily focused on Canada, shifting expectations around US federal cannabis policy are increasingly influencing how investors view its long-term optionality and capital...